Lacosamide in Migraine Prevention

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Our aim is to study the effect of lacosamide as a preventive treatment of migraine by assessing the change in the disease duration, attack frequency, and duration, pain intensity assessed by visual analogic scale, and The Migraine Disability Assessment Test after 90 days of regular use of 50 mg lacosamide twice daily. in patients diagnosed to have migraine based upon the International Classification of Headache Disorders (ICHD) 3rd edition.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kafrelsheikh University
• Treatments: Lacosamide

Criteria

Inclusion Criteria:

• Naive migraine patients according to the International Classification of Headache Disorders 3rd edition aged 10-55 years,

Exclusion Criteria:

• Patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors.

• patients with major systemic diseases such as malignancy, collagen diseases, liver diseases, and renal diseases.

• patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/Hg on at least three different occasions, diabetes (fasting plasma glucose level >126 mg/dl and/or a casual plasma glucose >200 mg/dl and/or HbA1C more than 6.5.

• patients with valvular and ischemic heart diseases,

• patients who received prophylactic treatment for migraine,

• patients with any contraindications to lacosamide.